European approval for hydrophobic acrylic IOL


Bausch + Lomb introduced the enVista toric IOL for astigmatism correction for European patients at the 2012 ESCRS Congress in Milan.

Bausch + Lomb introduced the enVista toric IOL for astigmatism correction for European patients at the 2012 ESCRS Congress in Milan.

The fenestrated step-vaulted haptics and 56 degrees contact angle enhances rotational stability. A recent clinical trial demonstrated the absolute mean rotation at six-month visit was 3 degrees and mean decentration was 0.28 mm, compared to 0.5 mm with the current market-leading IOL.

Dr Luis Cadarso, Clinica Cadarso, Pontevedra, Spain, said, " The rotational stability of a toric IOL is critical to providing the best possible outcome for a patient. If the lens rotates a patient’s vision will become suboptimal,” said Luis Cadarso, Clinica Cadarso, Pontevedra, Spain. “In my experience, the new enVista TORIC is very stable. Since this lens is also clinically proven to be glistening-free, it allows me to provide better, more consistent vision for my astigmatic patients.”

Dr Cal Roberts, executive vice president and chief medical officer at B+L, commented, "The enVista lens is manufactured using a glistening-free, foldable hydrophobic acrylic IOL material developed by Advanced Vision Science, a Santen subsidiary. Together, our unique Advanced Optics technology, clinically proven glistening-free material, and superior rotational stability, deliver optimal outcomes to patients. The addition of this new lens to our portfolio means that Bausch + Lomb now offers surgeons a more complete range of IOLs to meet their patients’ needs.”

Recent Videos
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
© 2024 MJH Life Sciences

All rights reserved.